Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
- 30 November 2010
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 36 (7), 566-575
- https://doi.org/10.1016/j.ctrv.2010.03.003
Abstract
No abstract availableThis publication has 64 references indexed in Scilit:
- Head and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427Head & Neck, 2009
- Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibilityNucleic Acids Research, 2008
- Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cellsNucleic Acids Research, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Deletion Mutants of Poly(ADP-Ribose) Polymerase A Support a Model of Cyclic Association and Dissociation of Enzyme from DNA Ends During DNA RepairBiochemistry, 1994
- Differential response of human and rodent cell lines to chemical inhibition of the repair of potentially lethal damageRadiation and Environmental Biophysics, 1989
- Radiation Damage Repair Capacity of A Human Germ-cell Tumour Cell Line: Inhibition by 3-aminobenzamideInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1987
- Differential Radiosensitization of Human Tumour Cells by 3-aminobenzamide and Benzamide: Inhibitors of Poly(ADP-ribosylation)International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1986